Fred Alger Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Fred Alger Management’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-141,993	Closed	-$9.77M	–	646
2014 Q3	$9.77M	Sell	141,993 -20,872	-13%	-$1.49M	0.05%	257
2014 Q2	$17.1M	Sell	162,865 -48,537	-23%	-$4.13M	0.08%	204
2014 Q1	$17.5M	Sell	211,402 -124,172	-37%	-$11.5M	0.09%	225
2013 Q4	$21.7M	Sell	335,574 -34,304	-9%	-$2.04M	0.11%	206
2013 Q3	$23.4M	Sell	369,878 -9,392	-2%	-$462K	0.13%	181
2013 Q2	$15.9M	Buy	+379,270	New	+$17.3M	0.09%	227

Other funds holding GEVA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fred Alger Management's GEVA Position: Q4 2014 in Review

Fred Alger Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2014, closing a stake of 141,993 shares — an estimated $9.77M sold.

Fred Alger Management first reported a position in GEVA in Q2 2013 and held it in 6 quarters. The position peaked at $23.4M in Q3 2013. 126 funds tracked by Wall St. Rank hold GEVA as of Q4 2014.

Fred Alger Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2014 after selling out during the quarter.
Fred Alger Management sold 141,993 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2014, an estimated $9.77M.
Fred Alger Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 6 quarters.
Fred Alger Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $23.4M in Q3 2013.
126 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2014.

Based on Fred Alger Management's 13F filing for Q4 2014, filed 17 Feb 2015.